First published: 2nd May 2023

Cumulus Neuroscience is proud to announce the appointment of industry veteran Tina Sampath as Chief Commercial Officer (CCO), marking a critical milestone in our expansion strategy. Tina is charged with driving commercial growth, overseeing strategic partnerships, marketing operations and corporate communications. Her experience developing strategies for major biopharma, diagnostic and med tech companies is essential as we look to scale our biopharma collaborations, supporting the accelerated development of precision central nervous system (CNS) medicines.

“Cumulus is in a moment of momentum, and Tina’s extensive commercial leadership experience will be essential as we accelerate growth in the biopharma space and invest in R&D,” said Aman Bhatti, MD, Chief Executive Officer, Cumulus. “Tina’s demonstrated success spanning multiple therapeutic areas, diagnostics and digital health technologies is perfectly suited for our needs today and into the future, as we pursue our mission to accelerate the discovery and development of innovative CNS medicines.”

Tina brings more than 23 years of experience as a commercial leader at well-known biopharma, diagnostic and med tech companies, including Gilead Sciences (via acquisition of CV Therapeutics 2009), Pfizer (via $14B acquisition of Medivation in 2016) and AliveCor. Additionally, she was essential in the acquisition of Blue Earth Diagnostics, which was acquired by Bracco for $450M in 2019. Tina is an award-winning marketing executive with a proven track record of creating growth and profitability through the development and execution of innovative data-driven, integrated, cross-channel marketing strategies.

“While we've seen major advances in other therapeutic areas enabling personalized medicine, to date, this has not been the case for the majority of patients living with neurodegenerative and neuropsychiatric diseases,” commented Sampath. “By enabling decentralized clinical studies, and with the potential to enrich data sets with EEG-derived digital biomarkers, the Cumulus Platform can exponentially accelerate drug development for our biopharma partners – and has the potential to transform the CNS space the way next generation sequencing (NGS) and precision diagnostics have transformed oncology.”

“I look forward to drawing on my experience to further establish Cumulus as the market leader, driving growth in the near and long term,” she added.

The growth of the executive leadership bench follows the recent establishment of the company’s Boston office to better support its partnerships with Boston-area biopharma innovators. By enabling remote monitoring of patients across multiple domains of brain function, Cumulus supports precision in CNS clinical trials for its partners. Its first-in-class neuroassessment platform improves the characterization of a drug's effect on the brain and provides more frequent, objective assessments – accelerating go/no-go decisions for development teams and enabling biopharma clinical researchers to understand the effect of varying doses on cognition, mood, memory, and language. The Cumulus electroencephalogram (EEG) synced digital platform utilizes a range of validated cognitive and behavioral tasks, precisely synchronized to a dry-sensor EEG for use in-clinic or in unsupervised (at-home/remote) environments, allowing for increased ease-of-use for patients and caregivers.